Abstract
Introduction: Chronic obstructive disease of the lungs (CODL) is one of the leading cases of morbidity and mortality all over the world. It is one of the causes which may form the basis of sudden death, it serves as disturbance of cardiac contractions rhythm. Aim of the research is to evaluate the effect of adrenoreceptor – nebivaolol by selective blocker β1 on pulmonary hypertension degree in patients with chronic obstructive disease of the lungs. Material and methods: 60 patients with chronic obstructive disease of the lungs of III-IV stage in exacerbation phase were enrolled in the study. The patients were subdivided into 2 groups: group A for comparison (n-25) and group B for study (n=35). The patients of both groups received standard therapy, directed to elimination of inflammatory process and improvement of bronchial permeability: antibiotics, broncholytics, mucolytics. The patients of group B were treated with nebivaolol in the dosage 10 mg 24 hours (5 mg dose 2 times 24 hours) for 14 days. Results: In absence of negative effect on hemodynamic indexes, electrophysiological parameters and sporometric data reveal changes in the rate of cardiac contractions to adequate values and significant increase of tolerance to physical exertion in 2 weeks after taking nebivaolol. Decrease of heart rate correlates with decrease of pulmonary hypertension. Conclusion: Taking into account the received findings nebivaolol can be recommended for treatment of patients with chronic obstructive disease of the lungs and pulmonary hypertension.
Highlights
Chronic obstructive disease of the lungs (CODL) is one of the leading cases of morbidity and mortality all over the world [1 - 4]. It is one of the causes which may form the basis of sudden death, it serves as disturbance of cardiac contractions rhythm
The aim of the research is to evaluate the effect of adrenoreceptor – nebivaolol by selective blocker β1 on pulmonary hypertension degree in patients with chronic obstructive disease of the lungs
Among the factors causing the development of arrhythmia are considered to be the following: aggravation of bronchial permeability, medicines prescribed to patients with chronic obstructive disease of the lungs, dysfunction of autonomic conductive cardiac system, ischemic heart disease, arterial hypertonia, dysfunction of the left ventricle (LV) and right ventricle (RV), increase of catecholamine level in the blood and development of hypoxemia
Summary
Chronic obstructive disease of the lungs (CODL) is one of the leading cases of morbidity and mortality all over the world [1 - 4]. It is one of the causes which may form the basis of sudden death, it serves as disturbance of cardiac contractions rhythm. CODL is associated with several other diseases, such as cardiovascular diseases, osteoporosis, diabetes, and metabolic syndrome, more commonly than expected by chance. These associations are greater than expected from common aetiological factors, such as smoking, suggesting that these comorbidities may be causally associated with the mechanisms of CODL. Systemic effects and comorbidities of CODL increase both the risks of hospitalisation and mortality and the costs, and are a topic of increasing concern
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Pharmacology, Phytochemistry and Ethnomedicine
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
